Lipophilic prodrug conjugates allow facile and rapid synthesis of high-loading capacity liposomes without the need for post-assembly purification

References

• Allen TM, Cullis PR. (2004). Drug delivery systems: entering the mainstream. Science 303:1818–22
   PubMed Web of Science ®Google Scholar
• Andresen T, Jensen S, Jorgensen K. (2005). Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 44:68–97
   PubMed Web of Science ®Google Scholar
• Arouri A, Mouritsen O. (2012). Phospholipase A(2)-susceptible liposomes of anticancer double lipid-prodrugs. Eur J Pharm Sci 45:408–20
   PubMed Web of Science ®Google Scholar
• Barenholz Y. (2001). Liposome application: problems and prospects. Curr Opin Colloid Interface Scie 6:66–77
   Web of Science ®Google Scholar
• Bencharit S, Morton CL, Hyatt JL, et al. (2003). Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition. Chem Biol 10:341–9
   PubMed Web of Science ®Google Scholar
• Bildstein L, Dubernet C, Couvreur P. (2011). Prodrug-based intracellular delivery of anticancer agents. Adv Drug Deliv Rev 63:3–23
   PubMed Web of Science ®Google Scholar
• Borden MA, Martinez GV, Ricker J, et al. (2006). Lateral phase separation in lipid-coated microbubbles. Langmuir 22:4291–7
   PubMed Web of Science ®Google Scholar
• Cao Z, Tong R, Mishra A, et al. (2009). Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew Chem Int Ed 48:6494–8
   PubMed Web of Science ®Google Scholar
• Caskey C, Hu X, Ferrara K. (2011). Leveraging the power of ultrasound for therapeutic design and optimization. J Control Release 156:297–306
   PubMed Web of Science ®Google Scholar
• Charles W, Young ESB. (1973). Analysis of tissue esterases from patients with Hodgkin's disease and other types of advanced cancer by isoelectric focusing in acrylamide gel. Cancer Res 33:2692–700
   PubMed Web of Science ®Google Scholar
• Chernysheva NB, Tsyganov DV, Philchenkov AA, et al. (2012). Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents. Bioorg Med Chem Lett 22:2590–3
   PubMed Web of Science ®Google Scholar
• Coimbra M, Isacchi B, Van Bloois L, et al. (2011). Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. Int J Pharm 416:433–42
   PubMed Web of Science ®Google Scholar
• Crielaard BJ, Van Der Wal S, Le HT, et al. (2012). Liposomes as carriers for colchicine-derived prodrugs: vascular disrupting nanomedicines with tailorable drug release kinetics. Eur J Pharm Sci 45:429–35
   PubMed Web of Science ®Google Scholar
• Demetzos C. (2008). Differential scanning calorimetry (DSC): a tool to study the thermal behavior of lipid bilayers and liposomal stability. J Liposome Res 18:159–73
   PubMed Web of Science ®Google Scholar
• Drummond DC, Meyer O, Hong K, et al. (1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691–744
   PubMed Web of Science ®Google Scholar
• Edsall AB, Agoston GE, Treston AM, et al. (2007). Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate. J Med Chem 50:6700–5
   PubMed Web of Science ®Google Scholar
• Fritze A, Hens F, Kimpfler A, et al. (2006). Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta (BBA) Biomembr 1758:1633–40
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. (2004). Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 56:1177–92
   PubMed Web of Science ®Google Scholar
• Gao W, Hu C-MJ, Fang R, Zhang L. (2013). Liposome-like nanostructures for drug delivery. J Mater Chem B 1:6569–6585
   Web of Science ®Google Scholar
• Grabielle-Madelmont C, Lesieur S, Ollivon M. (2003). Characterization of loaded liposomes by size exclusion chromatography. J Biochem Biophys Methods 56:189–217
   PubMedGoogle Scholar
• Gulati M, Grover M, Singh S, Singh M. (1998). Lipophilic drug derivatives in liposomes. Int J Pharm 165:129–68
   Web of Science ®Google Scholar
• Heidel J, Davis M. (2011). Clinical developments in nanotechnology for cancer therapy. Pharm Res 28:187–99
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Gil F, Leno E, et al. (2009). Interaction between human serum esterases and environmental metal compounds. Neurotoxicology 30:628–35
   PubMed Web of Science ®Google Scholar
• Huang SL. (2008). Liposomes in ultrasonic drug and gene delivery. Adv Drug Deliv Rev 60:1167–76
   PubMed Web of Science ®Google Scholar
• Huth U, Schubert R, Peschka-Suss R. (2006). Investigating the uptake and intracellular fate of pH-sensitive liposomes by flow cytometry and spectral bio-imaging. J Control Release 110:490–504
   PubMed Web of Science ®Google Scholar
• Ikeda A, Kawai Y, Kikuchi J-I, et al. (2011). Formation and regulation of fullerene-incorporation in liposomes under the phase transition temperature. Org Biomol Chem 9:2622–7
   PubMed Web of Science ®Google Scholar
• Immordino ML, Dosio F, Cattel L. (2006). Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1:297–315
   PubMed Web of Science ®Google Scholar
• Jahnig F. (1984). Lipid exchange between membranes. Biophys J 46:687–94
   PubMed Web of Science ®Google Scholar
• Jordan MA, Thrower D, Wilson L. (1992). Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles – implications for the role of microtubule dynamics in mitosis. J Cell Sci 102:401–16
   PubMed Web of Science ®Google Scholar
• Kuznetsova NR, Svirshchevskaya EV, Skripnik IV, et al. (2013). Interaction of liposomes bearing a lipophilic doxorubicin prodrug with tumor cells. Biochem (Moscow) Suppl Ser A Membr Cell Biol 7:12–20
   Google Scholar
• Lu Y, Chen J, Xiao M, et al. (2012). An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res 29:2943–71
   PubMed Web of Science ®Google Scholar
• Maeda H. (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189–207
   PubMedGoogle Scholar
• Maeda H. (2010). Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconj Chem 21:797–802
   PubMed Web of Science ®Google Scholar
• Magedov IV, Frolova L, Manpadi M, et al. (2011). Anticancer properties of an important drug lead podophyllotoxin can be efficiently mimicked by diverse heterocyclic scaffolds accessible via one-step synthesis. J Med Chem 54:4234–46
   PubMed Web of Science ®Google Scholar
• Magedov IV, Manpadi M, Slambrouck SV, et al. (2007). Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by a one-step multicomponent synthesis. J Med Chem 50:5183–92
   PubMed Web of Science ®Google Scholar
• Mahato R, Tai W, Cheng K. (2011). Prodrugs for improving tumor targetability and efficiency. Adv Drug Deliv Rev 63:659–70
   PubMed Web of Science ®Google Scholar
• Na K, Lee E-Y, Lee H-J, et al. (2009). Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma. Proteomics 9:3989–99
   PubMed Web of Science ®Google Scholar
• Niu G, Cogburn B, Hughes J. (2010). Preparation and characterization of doxorubicin liposomes. In: Grobmyer SR, Moudgil BM, eds. Cancer nanotechnology. Totowa (NJ): Humana Press, 211–19
   Google Scholar
• Ohsumi K, Hatanaka T, Fujita K, et al. (1998). Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues. Bioorg Med Chem Lett 8:3153–8
   PubMed Web of Science ®Google Scholar
• Pagano RE, Gershfeld NL. (1972). Physical chemistry of lipid films at the air-water interface. II. Binary lipid mixtures. The principles governing miscibility of lipids in surfaces. J Phys Chem 76:1238–43
   PubMed Web of Science ®Google Scholar
• Pedersen PJ, Adolph SK, Subramanian AK, et al. (2010). Liposomal formulation of retinoids designed for enzyme triggered release. J Med Chem 53:3782–92
   PubMed Web of Science ®Google Scholar
• Petrache HI, Dodd SW, Brown MF. (2000). Area per lipid and acyl length distributions in fluid phosphatidylcholines determined by 2H NMR spectroscopy. Biophys J 79:3172–92
   PubMed Web of Science ®Google Scholar
• Petros RA, Desimone JM. (2004). Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 9:615–27
   Web of Science ®Google Scholar
• Pili B, Reddy LH, Bourgaux C, et al. (2010). Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation. Nanoscale 2:1521–6
   PubMed Web of Science ®Google Scholar
• Pitt WG, Husseini GA, Staples BJ. (2004). Ultrasonic drug delivery – a general review. Expert Opin Drug Deliv 1:37–56
   PubMedGoogle Scholar
• Pollock S, Antrobus R, Newton L, et al. (2010). Uptake and trafficking of liposomes to the endoplasmic reticulum. FASEB J 24:1866–78
   PubMed Web of Science ®Google Scholar
• Rooseboom M, Commandeur J, Vermeulen N. (2004). Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 56:53–102
   PubMed Web of Science ®Google Scholar
• Ruiz A, Hernandez Y, Cabal C, et al. (2013). Biodistribution and pharmacokinetics of uniform magnetite nanoparticles chemically modified with polyethylene glycol. Nanoscale 5:11400–8
   PubMed Web of Science ®Google Scholar
• Ruysschaert T, Marque A, Duteyrat JL, et al. (2005). Liposome retention in size exclusion chromatography. BMC Biotechnol 5:11
   PubMed Web of Science ®Google Scholar
• Schrama D, Reisfeld R, Becker J. (2006). Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5:147–59
   PubMed Web of Science ®Google Scholar
• Silverman RB. (2004). The organic chemistry of drug design and drug action. London: Elsevier Academic Press
   Google Scholar
• Singh Y, Palombo M, Sinko PJ. (2008). Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem 15:1802–26
   PubMed Web of Science ®Google Scholar
• Song LY, Ahkong QF, Rong Q, et al. (2002). Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. Biochim Biophys Acta 1558:1–13
   PubMed Web of Science ®Google Scholar
• Tartis M, Kruse D, Zheng H, et al. (2008). Dynamic microPET imaging of ultrasound contrast agents and lipid delivery. J Control Release 131:160–6
   PubMed Web of Science ®Google Scholar
• Tartis M, Mccallan J, Lum A, et al. (2006). Therapeutic effects of paclitaxel-containing ultrasound contrast agents. Ultrasound Med Biol 32:1771–80
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Weissig V, eds. (2003). Liposomes. A practical approach. Oxford: Oxford University Press
   Google Scholar
• Van Wezel AP, Cornelissen G, Van Miltenburg JK, Opperhuizen A. (1996). Membrane burdens of chlorinated benzenes lower the main phase transition temperature in dipalmitoyl-phosphatidylcholine vesicles: implications for toxicity by narcotic chemicals. Environ Toxicol Chem 15:203–12
   Web of Science ®Google Scholar
• Xu H, Deng Y, Chen D, et al. (2008). Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives. J Control Release 130:238–45
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Jaggi M, Chauhan SC. (2012). Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today 17:71–80
   PubMed Web of Science ®Google Scholar